Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $36.88 USD
Change Today -1.44 / -3.76%
Volume 1.8M
HZNP On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 2:20 PM 07/29/15 All times are local (Market data is delayed by at least 15 minutes).

horizon pharma plc (HZNP) Snapshot

Open
$37.87
Previous Close
$38.32
Day High
$38.12
Day Low
$36.50
52 Week High
07/20/15 - $39.49
52 Week Low
07/29/14 - $7.85
Market Cap
5.7B
Average Volume 10 Days
3.0M
EPS TTM
$-0.05
Shares Outstanding
154.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for HORIZON PHARMA PLC (HZNP)

horizon pharma plc (HZNP) Related Businessweek News

No Related Businessweek News Found

horizon pharma plc (HZNP) Details

Horizon Pharma plc, a specialty biopharmaceutical company, engages in identifying, developing, acquiring or in-licensing, and commercializing medicines for the treatment of arthritis, pain, inflammatory, and/or orphan diseases in the United States and internationally. The company offers ACTIMMUNE for reducing the frequency and severity of serious infections associated with chronic granulomatous disease; DUEXIS, a proprietary tablet formulation for the relief of signs and symptoms of rheumatoid arthritis (RA) and osteoarthritis (OA), and to decrease the risk of developing upper gastrointestinal ulcers in patients who are taking ibuprofen for these indications; PENNSAID for the treatment of pain of OA of the knee; and VIMOVO, a proprietary fixed-dose multi-layer delayed-release tablet for the relief of the signs and symptoms of OA, RA, and ankylosing spondylitis (AS). It also provides RAYOS/LODOTRA, a proprietary delayed-release formulation of low-dose prednisone for the treatment of moderate to severe active RA in adults when accompanied by morning stiffness, as well as for the treatment of polymyalgia rheumatica, psoriatic arthritis, AS, asthma, chronic obstructive pulmonary disease, and various other conditions. The company has a collaboration agreement with Fox Chase Cancer Center to study ACTIMMUNE in combination with PD-1/PD-L1 inhibitors in various forms of cancer. Horizon Pharma plc was founded in 2005 and is headquartered in Dublin, Ireland.

605 Employees
Last Reported Date: 05/8/15
Founded in 2005

horizon pharma plc (HZNP) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $982.3K
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $210.9K
Chief Business Officer and Executive Vice Pre...
Total Annual Compensation: $492.0K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $396.3K
Chief Commercial Officer and Executive Vice P...
Total Annual Compensation: $194.5K
Compensation as of Fiscal Year 2014.

horizon pharma plc (HZNP) Key Developments

Horizon Pharma plc Announces Collaboration with Fox Chase Cancer Center to Study ACTIMMUNE (interferon Gamma 1b) in Combination with PD-1/PD-L1 Inhibitors in Various Forms of Cancer

Horizon Pharma plc announced a collaboration with Fox Chase Cancer Center to study ACTIMMUNE (interferon gamma-1b) in combination with PD-1/PD-L1 inhibitors in various forms of cancer including advanced urothelial carcinoma (bladder cancer) and renal cell carcinoma. Preclinical cell line research has indicated that interferon gamma enhances cellular PD-L1 expression on endothelial cells (inner lining of the blood vessel) and on some tumor cells. By enhancing cellular PD-L1 expression on tumor cells, interferon gamma may promote or enhance the effect of the PD-1 or PD-L1 inhibitors. The first study being planned as part of the collaboration will be a dose-ranging study to determine a suitable dose for ACTIMMUNE with PD-1/PD-L1 inhibition. Once the ideal combination strategy is determined, the investigators intend to expand the study to include patients with metastatic bladder and renal cell carcinomas. Additional studies are expected to follow depending on initial results.

Horizon Pharma plc Provides Sales Guidance for the Second Quarter Ended June 30, 2015 and Revises Earnings Guidance for the Full-Year 2015

Horizon Pharma plc provided sales guidance for the second quarter ended June 30, 2015 and revised earnings guidance for the full-year 2015. For the second quarter of 2015, the company estimates net sales in the range of $170 million to $172 million. For the full year of 2015, the company now estimates net sales in the range of $660 million to $680 million against $590 million to $610 million expected earlier. The company now estimates adjusted EBITDA in the range of $265 million to $280 million against $235 million to $250 million expected earlier.

Horizon Pharma plc Appoints Tina E. Ventura as Vice President, Investor Relations

Horizon Pharma plc appointed Tina E. Ventura as vice president, investor relations, reporting to John B. Thomas, executive vice president, strategy and investor relations, effective immediately. Ventura brings nearly two decades of investor relations and communications experience in the pharmaceutical, nutrition, diagnostic and medical device industries to Horizon. Most recently, Ventura was divisional vice president, investor relations at Abbott Laboratories where she was responsible for communicating the company's investment identity to Wall Street as well as maintaining close relationships with sell-side analysts and buy-side investors.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HZNP:US $36.88 USD -1.44

HZNP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Endo International PLC $85.88 USD -1.75
Pfizer Inc $35.77 USD +0.415
View Industry Companies
 

Industry Analysis

HZNP

Industry Average

Valuation HZNP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 12.7x
Price/Book 7.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 12.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HORIZON PHARMA PLC, please visit www.horizonpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.